ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Files An 8-K Regulation FD Disclosure

Item7.01 Other Events.

On March30, 2017, Adaptimmune Therapeutics plc (the Company)
released an updated corporate presentation. The updated corporate
presentation materials are attached hereto as Exhibit99.1 and are
incorporated by reference herein.

The information in Item7.01 of this Form8-K (including
Exhibit99.1) shall not be deemed filed for purposes of Section18
of the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that section, nor shall it be
deemed incorporated by reference under the Securities Act of
1933, as amended, except as expressly set forth by specific
reference in such a filing, regardless of any general
incorporation language in any such filing, unless the Company
expressly sets forth in such filing that such information is to
be considered filed or incorporated by reference therein.

Item 8.01. Other Events.

On March27, 2017, the Company issued a press release announcing
the closing of its previously announced underwritten public
offering of its American Depositary Shares (ADSs). Adaptimmune
sold 15,700,223 ADSs at a price to the public of $4.20 per ADS,
which included 1,400,223 ADSs sold to the exercise of the
underwriters option to purchase up to 2,145,000 additional ADSs.
A copy of the press release is attached hereto as Exhibit99.2 and
is incorporated by reference herein.

Item 9.01 Financial Statements and
Exhibits.

(d) Exhibits. The following exhibits are furnished as part of
this Report on Form8-K:

About ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP)

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase their affinity to cancer-specific peptides, including its lead target peptides, NY-ESO-1 and MAGE-A10, in order to target and then destroy cancer cells in patients. The Company’s TCR therapeutic candidates are able to target intracellular, as well as extracellular cancer antigens. The TCRs consist of approximately two associated protein chains: the alpha and beta chains. Each of the chains has approximately two regions: a variable region and a constant region.

ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Recent Trading Information

ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) closed its last trading session up +0.10 at 5.03 with 533,888 shares trading hands.